Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q3 2020

Q3 2020 biggest moves
  • AFIBAFIB

    ACUTUS MED

    New listing

    3.2% of portfolio

  • SDGRSDGR

    Schrodinger

    Sold out

    was 3.6% of portfolio

  • NKTXNKTX

    Nkarta

    New listing

    1.8% of portfolio

  • CNCCNC

    Centene

    2.1× the shares

    now 2.6% of portfolio

95 changes in all

Top Holdings105 positions

Checking export access…
Activity:
??
INVITAE CORPDelisted
Bond
163.4M$267.7M6.5%——
1 qtr
New
95
MYL
MYLDelisted

MYLAN NV

13.3M$196.9M4.8%——
4 qtrssince 2019-Q4
Increased
61
IMMU
IMMUDelisted

IMMUNOMEDICS INC

2.3M$196M4.8%——
4 qtrssince 2019-Q4
Decreased
0
??
NEVRO CORPDelisted
Bond
115.8M$172.9M4.2%——
4 qtrssince 2019-Q4
Unchanged
0
HZNP
HZNPDelisted

HORIZON THERAPEUTICS PUB L

1.8M$142.4M3.5%——
4 qtrssince 2019-Q4
Decreased
0
AFIB
AFIBDelisted

ACUTUS MED INC

4.3M$129.4M3.2%——
1 qtr
New
84
149.6M$120.1M2.9%——
1 qtr
New
78
DF
DFPHUDelisted
Unit

DFP HEALTHCARE ACQUISITNS CO

10.5M$114.3M2.8%——
3 qtrssince 2020-Q1
Unchanged
0
CNC

Centene Corporation

1.8M$106.6M2.6%$60.32-3.30%
4 qtrssince 2019-Q4
Increased
83
MYOK
MYOKDelisted

MYOKARDIA INC

704,000$96M2.3%——
4 qtrssince 2019-Q4
Unchanged
0
??
NUVASIVE INCDelisted
Bond
85M$87.4M2.1%——
3 qtrssince 2020-Q1
Unchanged
0
??
DEXCOM INCDelisted
Bond
34M$85.9M2.1%——
4 qtrssince 2019-Q4
Unchanged
0
LRMR

Larimar Therapeutics, Inc.

5.1M$78M1.9%$12.85+18.05%
2 qtrssince 2020-Q2
Unchanged
0
NKTX

Nkarta, Inc.

2.4M$72.7M1.8%$30.060.00%
1 qtr
New
68
PCRX

Pacira BioSciences, Inc.

1.2M$72M1.8%$33.93+77.17%
3 qtrssince 2020-Q1
Decreased
0
64.8M$69.7M1.7%——
1 qtr
New
68
GRAY
GRAYDelisted

GRAYBUG VISION INC

5.3M$67.1M1.6%——
1 qtr
New
68
MIRM

Mirum Pharmaceuticals, Inc.

3.4M$66.5M1.6%$24.52-21.41%
4 qtrssince 2019-Q4
Unchanged
0
ALXN
ALXNDelisted

ALEXION PHARMACEUTICALS INC

579,248$66.3M1.6%——
2 qtrssince 2020-Q2
Increased
75
??
INSMED INCDelisted
Bond
61M$66M1.6%——
3 qtrssince 2020-Q1
Unchanged
0
$4.1B
AUM
105
Positions
Q3 2020
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q1$3,151,113,0000.539146165786%
2020-Q2$3,433,887,0008.97378164477%
2020-Q3$4,106,901,00019.5991889075%
Activity profile
$ moved · Q3'20
New49%Increased6%Decreased17%Exited27%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.7 quarters
<1Q29%1-4Q71%1-2Y0%2Y+0%

Deerfield Management Company, L.P. manages $4.1B across 105 positions as of Q3 2020. Top holdings: INVITAE CORP (6.5%), MYL (4.8%), IMMU (4.8%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$4B
INVITAE CORP6.52%
MYL4.79%
IMMU4.77%
NEVRO CORP4.21%
HZNP3.47%
AFIB3.15%
AERIE PHARMA2.92%
DFPHU2.78%
CNC2.60%
MYOK2.34%
Other2.13%

Portfolio allocation by GICS sector

Sectors3
Unknown53.32%
Healthcare45.01%
Financial Services1.66%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Unknown, Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used